Abstract:1 – The mythical and theological origin of physico-mathematical spaces; the geometrization of time Abstract There is no mathematical plane nor space in Euclid's geometry. Lines are traced, extended, intersected on a plane, an “apeiron” (it has no boundary), which is “practiced” but not mathematized. These lines have no thickness, they intersect in a point, that is a sign (“semeion”); they are objects of a mythical, ideal realm. Infinity is only potential: lines in the plane or endless sequences of numbers can be extended with no limit. Actual infinity will be fully conceptualizedThere is no mathematical plane nor space in Euclid's geometry. Lines are traced, extended, intersected on a plane, an “apeiron” (it has no boundary), which is “practiced” but not mathematized. These lines have no thickness, they intersect in a point, that is a sign (“semeion”); they are objects of a mythical, ideal realm. Infinity is only potential: lines in the plane or endless sequences of numbers can be extended with no limit. Actual infinity will be fully conceptualized much later, in the theological debate of late middle age, as an attribute of God. How does actual infinity relate to or how can it be represented in the finite? The Renaissance Italian painters will show that this is possible: the projective limit of the newly invented linear perspective, first used in XIV century paintings of the Annonciation, shows the infinite in the finite and joins the infinity of God to the bodily, three dimensional presence of a human being, the Madonna. We will critically analyze paintings from Giotto to Piero della Francesca that show this joint invention of actual infinity and of mathematical spaces, which allows as well the expression of a new, corporeal humanity. Later, this theological invention will become the mathematics of Descartes' and Desargues' spaces, the science of Newton's infinities. In the XIX century, physics will extend this mystical creation of infinite space and time to the mathematical “phase space” of its new scientific rigor, based on an increasing mathematical unity of space and time.

Time and spaces from physics to biology : Ontogenesis , phylogenesis and the formation of “ sense ”

Hiding in plain sight: Optimizing topoisomerase IIα inhibitors into Hsp90β selective binders

In silico identification of small molecule modulators for disruption of Hsp90-Cdc37 protein-protein interaction interface for cancer therapeutic application

Insight into the structural and dynamic properties of novel HSP90 inhibitors through DFT calculations and molecular dynamics simulations

[Brown fat and brain functions].

BET 3: Suxamethonium (succinylcholine) for RSI and intubation in head injury

Rational design of peptide inhibitors targeting HSP90–CDC37 protein–protein interaction

Physical and genetic analysis of the herpes simplex virus DNA polymerase locus.

The Investigation of Hsp90 C‐terminal inhibitors containing Amide bioisosteres

Inhibition of the HSP90 homodimerization and HSP90-HIF1α interactions by employing small molecules at C-terminal ATP binding site of HSP90

Design, synthesis and biological studies of new isoxazole compounds as potent Hsp90 inhibitors

Small-molecule dual inhibitors targeting heat shock protein 90 for cancer targeted therapy

Heat Shock Protein 90 (HSP90) Inhibitors as Anticancer Medicines: A Review on the Computer-Aided Drug Discovery Approaches over the Past Five Years

Structure-based discovery of small molecule inhibitors of FKBP51-Hsp90 protein-protein interaction

Discovery and development of heat shock protein 90 inhibitors.

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

[Celiac disease in adults associated with active chronic cirrhogenic hepatitis].

Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery

Hsp90 Inhibitors as Anti-Cancer Agents, from Basic Discoveries to Clinical Development

Probing some recent natural compounds from Phellinus baumii, Colletotrichum sp. and Ligustrum lucidum as heat shock protein 90 inhibitors

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?